Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.

@article{Hudes1999VinblastineVV,
  title={Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.},
  author={Gary R. Hudes and L awrence H. Einhorn and Edgar D. Ross and A Balsham and Patrick j. Loehrer and Heather Ramsey and John David Sprandio and M Entmacher and William Dugan and Rafat Ansari and Fabrizio Leonardo Monaco and Moneer K. Hanna and Bruce J. Roth},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1999},
  volume={17 10},
  pages={
          3160-6
        }
}
PURPOSE To compare vinblastine versus the combination of vinblastine plus estramustine as treatment for patients with hormone-refractory prostate cancer (HRPC). PATIENTS AND METHODS A total of 201 patients with metastatic prostate cancer, progressive after hormonal therapy and antiandrogen withdrawal (if prior antiandrogen treatment), were randomized to receive vinblastine (V) 4 mg/m(2) by intravenous bolus weekly for 6 weeks followed by 2 weeks off, either alone or together with estramustine… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 57 CITATIONS

FILTER CITATIONS BY YEAR

2000
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 2 Citations per year over the last 3 years

Similar Papers

Loading similar papers…